XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect. Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program. BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL Phase 2 clinical trial of XPro™ (XPro1595) in patients with early Alzheimer's disease encompassing both mild cognitive impairment (MCI) and mild Alzheimer’s disease dementia. The new MRI findings add to a growing body of evidence supporting XPro™’s precision-medicine development strategy, including the peer-reviewed publication of the Phase 2 MINDFuL results in NPJ Dementia, FDA End-of-Phase 2 alignment on an integrated Phase 2b/3 registrational pathway, and the recent grant of FDA Fast Track designation for XPro™ in early Alzheimer’s disease. CJ Barnum, VP of Neuroscience at INmune Bio, further added, "What we are seeing in MINDFuL is consistency across nearly every domain we measured: cognition, neuropsychiatric symptoms, blood biomarkers, patient-reported outcomes, and now both MRI measures of brain quality, gray matter and white matter. The chi-separation result is the latest signal in that convergent picture, and it carries an additional layer of significance: across multiple independent preclinical models, XPro’s most reliable and reproducible effect has been on myelin biology. The MINDFuL chi-separation result demonstrates a treatment effect on myelin in the full study population that strengthens in patients with elevated inflammatory biomarkers. This is not a surprise finding. It is exactly what the preclinical work predicted. We look forward to presenting the complete dataset at AAIC 2026." BACKGROUND: White Matter Opportunity in Neurodegenerative Disease Across multiple independent preclinical models of demyelination and neurological injury, white matter has consistently emerged as the most reliable and reproducible target of XPro™ response, with clear, documented effects on myelin volume and quality. While historical industry efforts in AD have focused heavily on gray matter pathology, white matter (WM) degeneration and myelin loss are increasingly recognized as fundamental, early contributors to cognitive decline. This structural degradation is not unique to Alzheimer's; it represents a primary pathological signature across a broad spectrum of neurological and neurodegenerative conditions such as Multiple Sclerosis (MS), Vascular Dementia, traumatic brain injury, and many rare CNS diseases where neuroinflammation drives destruction of oligodendrocytes and myelin integrity. Chi-separation MRI was included in the MINDFuL Phase 2 trial as a target engagement biomarker for white matter. This method was chosen given that the trial enrolled patients with MCI and mild AD, the disease stage at which white matter abnormalities are prominent and highly clinically relevant. Chi-separation is a recently validated imaging technique that resolves key challenges of conventional MRI myelin measurement and can be deployed across standard multi-site clinical infrastructure without requiring specialty scanners, making it a methodologically superior and operationally scalable measure of white matter biology. Statistically Significant Biomarker Results The blinded analysis, performed by an independent imaging core laboratory, revealed statistically significant treatment effect on myelin: Full mITT Population (N=200): After 24 weeks of treatment, XPro™-treated participants showed a statistically significant difference in myelin compared to placebo ( p=0.0028 ) with a medium effect size ( Cohen's d=0.46 ). This effect across the full treatment population reproduces XPro™'s most reliable preclinical signature, establishing target engagement in AD patients with a high degree of confidence. Biomarker-Enriched AD Population (N=100): In patients with amyloid-positivity and two or more elevated inflammatory biomarkers at baseline, the treatment effect strengthened further to a medium-to-large effect size ( Cohen's d=0.59; p=0.0098 ). This is the patient profile most directly aligned with XPro™'s anti-neuroinflammatory mechanism. "A statistically significant treatment effect on white matter across the full mITT population, strengthening further in inflammation-enriched patients, tells us that XPro™ is doing exactly what it is designed to do, with increased effect in patients we intend to treat in the registrational study,” said David Moss, Chief Executive Officer of INmune Bio. “Importantly, by successfully targeti